Yibei Xiao

1.2k total citations
60 papers, 766 citations indexed

About

Yibei Xiao is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Yibei Xiao has authored 60 papers receiving a total of 766 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 22 papers in Oncology and 10 papers in Organic Chemistry. Recurrent topics in Yibei Xiao's work include Cancer Immunotherapy and Biomarkers (14 papers), CAR-T cell therapy research (13 papers) and Peptidase Inhibition and Analysis (8 papers). Yibei Xiao is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), CAR-T cell therapy research (13 papers) and Peptidase Inhibition and Analysis (8 papers). Yibei Xiao collaborates with scholars based in China, United States and Singapore. Yibei Xiao's co-authors include Sheng Jiang, Yao Cheng, Tianyu Wang, Peng Yang, Kuojun Zhang, Ailong Ke, Wanheng Zhang, Wenjian Min, Huiyong Sun and Xiangyu Zhang and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Yibei Xiao

56 papers receiving 762 citations

Peers

Yibei Xiao
Peter R. McDonald United States
Anuradha Roy United States
Adolfo Cuesta United States
Wendy T. Collard United States
Sheng‐Wei Lin Taiwan
Amy Fung United States
Dasheng Wang United States
Junhai Xiao China
Frédéric Thuaud France
Thomas Grombacher Germany
Peter R. McDonald United States
Yibei Xiao
Citations per year, relative to Yibei Xiao Yibei Xiao (= 1×) peers Peter R. McDonald

Countries citing papers authored by Yibei Xiao

Since Specialization
Citations

This map shows the geographic impact of Yibei Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yibei Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yibei Xiao more than expected).

Fields of papers citing papers by Yibei Xiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yibei Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yibei Xiao. The network helps show where Yibei Xiao may publish in the future.

Co-authorship network of co-authors of Yibei Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Yibei Xiao. A scholar is included among the top collaborators of Yibei Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yibei Xiao. Yibei Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Shuo, Yang Pan, Siqi Zhang, et al.. (2025). Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept. Journal of the American Chemical Society. 147(39). 35638–35654. 2 indexed citations
2.
Wang, Dawei, Tong Chen, Kai Han, et al.. (2025). Targeting Protein Tyrosine Phosphatase Nonreceptor Type 2 with a Novel Inhibitor for the Treatment of Melanoma. Journal of Medicinal Chemistry. 68(22). 24649–24671.
3.
Zhang, Yanzhi, et al.. (2024). Development of novel imipridone derivatives with potent anti-cancer activities as human caseinolytic peptidase P (hClpP) activators. Bioorganic Chemistry. 153. 107765–107765. 4 indexed citations
4.
Sun, Chengliang, Yao Cheng, Jingwen Dong, et al.. (2024). Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents. Journal of Medicinal Chemistry. 68(1). 156–173. 3 indexed citations
5.
Sun, Chengliang, Yuling He, Gefei Wang, et al.. (2024). Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors. Journal of Medicinal Chemistry. 67(5). 3590–3605. 13 indexed citations
6.
Zhu, Yasheng, Yuxing Wu, Zeyu Cai, et al.. (2024). Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation. Journal of Medicinal Chemistry. 67(9). 7283–7300. 18 indexed citations
7.
Liu, Y.H., et al.. (2024). Precise Gene Knock‐In Tools with Minimized Risk of DSBs: A Trend for Gene Manipulation. Advanced Science. 11(28). e2401797–e2401797. 3 indexed citations
8.
9.
10.
Chen, Yuan, Xinyu Luo, Pingping Huang, et al.. (2023). Mammalian trans-editing factor ProX is able to deacylate tRNAThr mischarged with alanine. International Journal of Biological Macromolecules. 253(Pt 5). 127121–127121. 1 indexed citations
11.
Wang, Kaizhen, Hongtao Shen, Tianyu Wang, et al.. (2023). Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1. Bioorganic Chemistry. 138. 106682–106682. 5 indexed citations
12.
Min, Wenjian, Hongtao Shen, Tong Chen, et al.. (2023). Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment. European Journal of Medicinal Chemistry. 264. 116025–116025. 5 indexed citations
13.
Yuan, Kai, et al.. (2023). Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry. 66(23). 16235–16256. 4 indexed citations
14.
Zhu, Yasheng, Hao Shen, Hongtao Shen, et al.. (2023). Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC. Journal of Medicinal Chemistry. 66(10). 6849–6868. 22 indexed citations
15.
Zhu, Yasheng, Hao Shen, Jiaxing Li, et al.. (2023). Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance. Journal of Medicinal Chemistry. 66(21). 14633–14652. 17 indexed citations
16.
Yuan, Kai, Hongtao Shen, Zeyu Cai, et al.. (2023). Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry. 66(6). 4215–4230. 10 indexed citations
17.
Qiao, Fei, Xuefei Jiang, Huapeng Sun, et al.. (2022). Elucidation of the 1-phenethylisoquinoline pathway from an endemic conifer Cephalotaxus hainanensis. Proceedings of the National Academy of Sciences. 120(1). e2209339120–e2209339120. 10 indexed citations
18.
Yuan, Kai, Wenbin Kuang, Xiao Wang, et al.. (2022). Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer. Nature Communications. 13(1). 2903–2903. 13 indexed citations
19.
Sun, Chengliang, Mingxiao Yin, Yao Cheng, et al.. (2022). Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment. Journal of Medicinal Chemistry. 66(3). 2064–2083. 33 indexed citations
20.
Sun, Chengliang, Yao Cheng, Xiaojia Liu, et al.. (2022). Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. Acta Pharmaceutica Sinica B. 12(12). 4446–4457. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter R. McDonald Breakdown of academic impact, for papers by Anuradha Roy Breakdown of academic impact, for papers by Adolfo Cuesta Breakdown of academic impact, for papers by Wendy T. Collard Breakdown of academic impact, for papers by Sheng‐Wei Lin Breakdown of academic impact, for papers by Amy Fung Breakdown of academic impact, for papers by Dasheng Wang Breakdown of academic impact, for papers by Junhai Xiao Breakdown of academic impact, for papers by Frédéric Thuaud Breakdown of academic impact, for papers by Thomas Grombacher
Rankless by CCL
2026